SecBot SecBot
Insider Cluster (2 insiders) ·Filed Jul 6, 2026

IBRX

ImmunityBio, Inc.
NEUTRAL
Impact 2/10
Horizondays Processed3mo ago
Insider cluster: 2 insiders, $1.3M total
Actionable Insight • Neutral

The insider sales are negligible relative to company size and involve only directors, not executives. No bearish signal here. Monitor for any C-suite open-market sales or a material increase in volume that would exceed 0.1% of market cap.

DirectionNeutral
Confidencehigh
Horizondays
Final — all horizons settled through T+60d
IBRX ▲ +7.76% at T+60d
NEUTRAL call +7.76% · α vs SPY +5.77% · entry $8.76 → $9.44
Entry = T+0 close
Jul 6, 2026
via day close
T+1d
+0.46%
call +0.46% · α +0.77%
$8.80
settled 4mo ago
T+5d
-10.05%
call -10.05% · α -10.60%
$7.88
settled 4mo ago
T+20d
-20.66%
call -20.66% · α -23.82%
$6.95
settled 3mo ago
T+60d
+7.76%
call +7.76% · α +5.77%
$9.44
settled 29d ago

Price Chart

Loading chart...

Executive Summary

Two directors of ImmunityBio sold a combined ~$2.7M in open-market stock this week, following derivative exercises. The total sales represent only ~0.027% of the company's $9.9B market cap, making the cluster economically trivial and routine. No C-suite insiders participated, and the pattern suggests standard tax-related diversification rather than informed selling.

Key Financial Metrics

Direction
selling
Total Value
$2.7M
Insiders
2

Key Facts

  • Director Cheryl Cohen sold 131,210 shares at ~$9.50 for $1.25M on 2026-07-02
  • Director Christobel Selecky sold 159,478 shares at ~$9.02 for $1.44M on 2026-07-01, plus 1,000 shares at $9.00 for $9K on 2026-06-30
  • Total open-market sales: ~$2.7M, or 0.027% of market cap
  • Both directors exercised derivative securities (options) prior to selling, a common pattern for tax withholding
  • No C-suite officers (CEO, CFO, etc.) were involved in any trades

Financial Impact

Total insider sales of approximately $2.7M, representing 0.027% of the company's $9.9B market capitalization

dilutioninsider ownership

Risk Factors

  • No material risk from this cluster given the small size and non-executive participation

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
90% bullish (10 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-IBRX-1783408251596
8 reports for IBRX
Performance horizon
33% Hit rate @ T+60 1 of 3 directional calls Went positive at some point 2 of 4 best @ T+60▲ +19.12%Apr 9, 2026
Filters
Rows
Reports for IBRX — sortable, filterable
TypeNow
Oct 14, 2026
13d ago
8-K
BULLISH ★ 7/10
$10.00awaiting T+60—$8.63 (−13.70%)
Aug 4, 2026
12w ago
8-K
NEUTRAL ★ 5/10
$6.95awaiting T+60—$8.63 (+24.17%)
Jul 6, 2026
16w ago
Insider Cluster
NEUTRAL ★ 2/10
$8.76 $9.44▲ +7.76%▲ +5.77%$8.63 (−1.48%)
Jul 1, 2026
16w ago
Insider Cluster
NEUTRAL ★ 2/10
$9.44 $8.52▼ −9.75%▼ −12.54%$8.63 (−8.58%)
May 18, 2026
23w ago
8-K
BULLISH ★ 5/10
$7.76 $7.65▼ −1.42%▼ −7.71%$8.63 (+11.21%)
Apr 9, 2026
28w ago
8-K
BULLISH ★ 8/10
$7.48 $8.91▲ +19.12%▲ +8.34%$8.63 (+15.37%)
Apr 6, 2026
29w ago
8-K
NEUTRAL ★ 4/10
$7.08 $9.20▲ +29.94%▲ +16.47%$8.63 (+21.89%)
Feb 28, 2026
34w ago
Institutional Cluster
BULLISH ★ 6/10
$10.44 $7.92▼ −24.14%▼ −33.46%$8.63 (−17.34%)
Showing 8 of 8

US Market Status

Market Closed — Opens Thu (9h 45m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 7, 2026